Curevac members of management sell shares to cover tax obligations from long term incentive program

TÜbingen, germany and boston, ma / accesswire / december 14, 2022 / curevac n.v. (nasdaq:cvac), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mrna"), today announced that chief executive officer franz-werner haas, chief financial officer pierre kemula and interim chief development officer ulrike gnad-vogt sold an aggregate of 103,775 curevac common shares.
CVAC Ratings Summary
CVAC Quant Ranking